123 related articles for article (PubMed ID: 37820046)
1. The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia.
Liao C; Nie J; Xu XJ; Zhang JY; Xu WQ; Song H; Shen HP; Shen DY; Zhao FY; Liang J; Miao J; Tang YM
Leuk Lymphoma; 2024 Jan; 65(1):91-99. PubMed ID: 37820046
[TBL] [Abstract][Full Text] [Related]
2. [Correlation study of blood drug concentration and nephrotoxicity on high dose methotrexate therapy in suggestion of diagnosis and treatment of childhood acute lymphoblastic leukemia in the 4th revised edition].
Cheng DH; Lu H; Zou XQ
Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):771-774. PubMed ID: 29050116
[No Abstract] [Full Text] [Related]
3. Solitary serum methotrexate level 36 hours post high-dose methotrexate: A safe, efficacious, and cost-effective strategy to monitor methotrexate toxicities in childhood leukemia in resource-limited centers.
Khera S; Kapoor R; Pramanik SK
Pediatr Blood Cancer; 2020 Jul; 67(7):e28387. PubMed ID: 32400952
[TBL] [Abstract][Full Text] [Related]
4. Age and high-dose methotrexate are associated to clinical acute encephalopathy in FRALLE 93 trial for acute lymphoblastic leukemia in children.
Dufourg MN; Landman-Parker J; Auclerc MF; Schmitt C; Perel Y; Michel G; Levy P; Couillault G; Gandemer V; Tabone MD; Demeocq F; Vannier JP; Leblanc T; Leverger G; Baruchel A
Leukemia; 2007 Feb; 21(2):238-47. PubMed ID: 17170721
[TBL] [Abstract][Full Text] [Related]
5. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.
Schrappe M; Reiter A; Henze G; Niemeyer C; Bode U; Kühl J; Gadner H; Havers W; Plüss H; Kornhuber B; Zintl F; Ritter J; Urban C; Niethammer D; Riehm H
Klin Padiatr; 1998; 210(4):192-9. PubMed ID: 9743952
[TBL] [Abstract][Full Text] [Related]
6. [Adverse effects of methotrexate in the treatment of acute lymphoblastic leukemia in Uyghur and Han children].
Hu WW; Nuriding H; Yan M
Zhongguo Dang Dai Er Ke Za Zhi; 2012 Nov; 14(11):852-5. PubMed ID: 23146734
[TBL] [Abstract][Full Text] [Related]
7. [Influence of thymidylate synthase gene polymorphisms on high-dose methotrexate-related toxicities in childhood acute lymphoblastic leukemia].
Zhu XJ; He XL; Wu YP; Zou RY; Li WL; Zou H; You YL; Liu H; Tian X
Zhongguo Dang Dai Er Ke Za Zhi; 2015 Jan; 17(1):11-4. PubMed ID: 25616285
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma.
Nakano T; Kobayashi R; Matsushima S; Hori D; Yanagi M; Suzuki D; Kobayashi K
Int J Hematol; 2021 May; 113(5):744-750. PubMed ID: 33389654
[TBL] [Abstract][Full Text] [Related]
9. Assessment of renal function during high-dose methotrexate treatment in children with acute lymphoblastic leukemia.
Ylinen E; Jahnukainen K; Saarinen-Pihkala UM; Jahnukainen T
Pediatr Blood Cancer; 2014 Dec; 61(12):2199-202. PubMed ID: 25174822
[TBL] [Abstract][Full Text] [Related]
10. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K
Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy, side effects and blood concentration monitoring of high-dose methotrexate in treatment of 180 children with acute lymphoblastic leukemia].
Wang H; Chi ZF; Li S; Wang XL; Hao LC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):949-52. PubMed ID: 21867621
[TBL] [Abstract][Full Text] [Related]
12. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
13. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
[TBL] [Abstract][Full Text] [Related]
14. Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate.
Rask C; Albertioni F; Schrøder H; Peterson C
Pediatr Hematol Oncol; 1996; 13(4):359-67. PubMed ID: 8837142
[TBL] [Abstract][Full Text] [Related]
15. Is hypoalbuminemia a risk factor for high-dose methotrexate toxicity in children with acute lymphoblastic leukemia?
Barakat S; Assem H; Salama M; Mikhael N; El Chazli Y
J Egypt Natl Canc Inst; 2022 Apr; 34(1):17. PubMed ID: 35434757
[TBL] [Abstract][Full Text] [Related]
16. Monitoring Of High-Dose Methotrexate (Mtx)-Related Toxicity and Mtx Levels in Children with Acute Lymphoblastic Leukemia: A Pilot-Study in Indonesia.
Sari NM; Rakhmilla LE; Bashari MH; Zazuli Z; Suryawan N; Susanah S; Reniarti L; Raspati H; Supriyadi E; Kaspers GJL; Idjradinata P
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2025-2031. PubMed ID: 34319023
[TBL] [Abstract][Full Text] [Related]
17. Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy.
Yanagimachi M; Goto H; Kaneko T; Naruto T; Sasaki K; Takeuchi M; Tanoshima R; Kato H; Yokosuka T; Kajiwara R; Fujii H; Tanaka F; Goto S; Takahashi H; Mori M; Kai S; Yokota S
Int J Hematol; 2013 Dec; 98(6):702-7. PubMed ID: 24241962
[TBL] [Abstract][Full Text] [Related]
18. [Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
Xu WQ; Tang YM; Fang CQ; Song H; Shi SW; Yang SL; Ren DT; Shen HQ; Qian BQ
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):15-8. PubMed ID: 15946502
[TBL] [Abstract][Full Text] [Related]
19. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
[TBL] [Abstract][Full Text] [Related]
20. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
